Compliance & Market Policy

Market-by-Market Status

Based on publicly available patent information; buyers should independently confirm the legal position in their jurisdiction.

Market	Semaglutide compound patent status	What we supply
Brazil	Expired March 2026; ANVISA has approved generic products	API to ANVISA-registered manufacturers for commercial production
China	Expired March 2026	API to licensed manufacturers for domestic and export programs
Australia	Patent / generic-entry window opens ~April 2027	Research-use quantities now; partnership supply for 2027 entry
United States	Compound patent in force until December 2031	Research use only (RUO); partnership with ANDA holders for post-2031 entry

Sales Policy

We supply licensed pharmaceutical manufacturers and qualified research institutions only.
We do not supply individuals, retailers or e-commerce consumer channels.
We do not promote or supply API for pharmacy compounding in the United States, where semaglutide compounding is no longer permitted under current FDA policy.
We do not make therapeutic claims; this site presents technical and quality information for B2B sourcing purposes.
Buyers must confirm their own regulatory obligations (registration, import permits, local patent position) before ordering.

Disclaimer: Patent and regulatory information on this page reflects public sources as of [Month Year] and may change. It is provided for general guidance and does not constitute legal advice. Consult qualified counsel for your specific transaction and market.

Compliance & Market Policy

Market-by-Market Status

Sales Policy

Discuss Your Market with Our Team